Cargando…

Viral mHealth​

Thousands of mHealth applications are developed every year, but few of these spread or ‘go viral’. Even clinical applications that provide health benefits and social value often linger after an initial pilot phase. An examination of common hindrances in low-income countries suggests that more subsid...

Descripción completa

Detalles Bibliográficos
Autor principal: Fölster, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5645666/
https://www.ncbi.nlm.nih.gov/pubmed/28838304
http://dx.doi.org/10.1080/16549716.2017.1336006
_version_ 1783271937470889984
author Fölster, Stefan
author_facet Fölster, Stefan
author_sort Fölster, Stefan
collection PubMed
description Thousands of mHealth applications are developed every year, but few of these spread or ‘go viral’. Even clinical applications that provide health benefits and social value often linger after an initial pilot phase. An examination of common hindrances in low-income countries suggests that more subsidies and education of health care personnel are insufficient solutions. Instead we propose better a priori screening of mHealth applications based on four criteria that may largely determine whether an mHealth application will spread. Further, we illustrate how using these criteria forms a good basis for involving ‘impact investors’ in the development of mHealth applications. This can reduce risks for public health care providers and increase the likelihood of success.
format Online
Article
Text
id pubmed-5645666
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-56456662017-10-24 Viral mHealth​ Fölster, Stefan Glob Health Action Current Debate Thousands of mHealth applications are developed every year, but few of these spread or ‘go viral’. Even clinical applications that provide health benefits and social value often linger after an initial pilot phase. An examination of common hindrances in low-income countries suggests that more subsidies and education of health care personnel are insufficient solutions. Instead we propose better a priori screening of mHealth applications based on four criteria that may largely determine whether an mHealth application will spread. Further, we illustrate how using these criteria forms a good basis for involving ‘impact investors’ in the development of mHealth applications. This can reduce risks for public health care providers and increase the likelihood of success. Taylor & Francis 2017-08-25 /pmc/articles/PMC5645666/ /pubmed/28838304 http://dx.doi.org/10.1080/16549716.2017.1336006 Text en © 2017 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Current Debate
Fölster, Stefan
Viral mHealth​
title Viral mHealth​
title_full Viral mHealth​
title_fullStr Viral mHealth​
title_full_unstemmed Viral mHealth​
title_short Viral mHealth​
title_sort viral mhealth​
topic Current Debate
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5645666/
https://www.ncbi.nlm.nih.gov/pubmed/28838304
http://dx.doi.org/10.1080/16549716.2017.1336006
work_keys_str_mv AT folsterstefan viralmhealth